The United Kingdom and the United States have finalized a landmark commercial pact that will keep zero duties on UK pharmaceutical products being sold in the US market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has committed to increase funding on pharmaceuticals through the public health system. This pledge ensures that import taxes on these key products will remain at zero for a duration of three years.
This development comes after previous statements to significantly raise duties on patented drug imports, with figures floated as high as 100%.
"This arrangement with the United Kingdom bolsters the worldwide climate for new treatments and establishes long-overdue equity to American-British drug exports," a statement noted.
Trade Importance
Medicines represent one of the Britain's most significant exports to the United States, which is by far the biggest market for leading companies like GSK and AstraZeneca.
Export figures indicate that in the year leading up to last September, the UK exported drugs valued at billions to the US. This value accounted for nearly one-fifth of total UK exports in that timeframe.
"This guarantee safeguards work, stimulates funding and facilitates the UK to become a worldwide center for life sciences," a minister commented.
Key British Pledges
The deal entails several specific pledges from the British government:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it deems new treatments to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a target to increase total public funding on drugs from 0.3 percent of GDP to 0.6% over the coming ten years.
- Payback Limit: The sum manufacturers must pay back to the NHS to prevent overspending will be capped at fifteen percent. Previously, rebates topped twenty percent.
Industry Background
This agreement follows a ongoing tension between the pharmaceutical industry and the ministers over drug pricing and approval rates.
This friction were heightened by arguments that US patients were charged several times more for the identical medicines than patients in the other developed nations.
Recently, several major manufacturing plans in the UK have been paused or cancelled, while multi-billion-dollar investments have been directed toward US facilities.
The Science Minister publicly accepted that the NHS must spend more on medicines, noting that its spending on drugs had shrunk as a proportion of its overall budget over the previous ten-year period.
